| Oct'19 | Oct'18 | Oct'17 | Oct'16 | Oct'15 | Oct'14 | Oct'13 |
|---|---|---|---|---|---|---|
Proceeds from sale of investments | ||||||
7,000 | 0 | 45,000 | 1,000 | 1,000 | - | 0 |
Cash flows from operating activities: | ||||||
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ||||||
621,000 | 165,000 | 102,000 | 335,000 | 513,000 | 392,000 | 457,000 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||
Depreciation | ||||||
96,000 | 103,000 | 92,000 | 85,000 | - | - | - |
Amortization | ||||||
212,000 | 207,000 | 133,000 | 49,000 | 99,000 | 84,000 | 77,000 |
Share-based compensation | ||||||
82,000 | 59,000 | 56,000 | 49,000 | 55,000 | 43,000 | 41,000 |
Excess tax (benefit) deficiency from share-based plans | ||||||
- | - | - | - | 4,000 | 4,000 | 0 |
Debt issuance expense | ||||||
0 | 0 | 9,000 | 0 | 0 | - | - |
Deferred tax expense (benefit) | ||||||
-2,000 | -789,000 | -47,000 | 17,000 | -163,000 | 23,000 | 14,000 |
Excess and obsolete inventory-related charges | ||||||
27,000 | 25,000 | 16,000 | 17,000 | 28,000 | 33,000 | 21,000 |
Gain on insurance proceeds received for damage to property, plant and equipment | ||||||
1,000 | 20,000 | 8,000 | -10,000 | 0 | 0 | - |
Goodwill impairment | ||||||
0 | 709,000 | 0 | 0 | - | - | - |
Asset impairment | ||||||
- | - | - | - | 0 | - | 1,000 |
Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash | ||||||
2,000 | 1,000 | -69,000 | 0 | 0 | - | - |
Other non-cash expense (income), net | ||||||
4,000 | -15,000 | -17,000 | -4,000 | -14,000 | 1,000 | -1,000 |
Changes in assets and liabilities: | ||||||
Accounts receivable | ||||||
26,000 | 89,000 | 11,000 | 42,000 | 20,000 | 25,000 | -44,000 |
Inventory | ||||||
92,000 | 61,000 | 4,000 | 22,000 | 25,000 | 31,000 | 53,000 |
Accounts payable | ||||||
13,000 | 22,000 | 15,000 | -8,000 | 18,000 | 32,000 | -24,000 |
Payment (to)/from Agilent, net | ||||||
- | - | - | - | 28,000 | -23,000 | 0 |
Employee compensation and benefits | ||||||
0 | 63,000 | -1,000 | 16,000 | 6,000 | 30,000 | 0 |
Deferred Revenue | ||||||
112,000 | 75,000 | 90,000 | 15,000 | -24,000 | - | - |
Income taxes payable | ||||||
-16,000 | 181,000 | 3,000 | -9,000 | 2,000 | 63,000 | -2,000 |
Retirement and post-retirement benefits | ||||||
-37,000 | -127,000 | -15,000 | -32,000 | -44,000 | -32,000 | 0 |
Other assets and liabilities | ||||||
-11,000 | -16,000 | 50,000 | 44,000 | 51,000 | 67,000 | 11,000 |
Net cash provided by operating activities | ||||||
998,000 | 555,000 | 328,000 | 420,000 | 376,000 | 563,000 | 566,000 |
Cash flows from investing activities: | ||||||
Investments in property, plant and equipment | ||||||
120,000 | 132,000 | 72,000 | 91,000 | 92,000 | 70,000 | 69,000 |
Proceeds from the sale of assets and divestitures | ||||||
2,000 | 29,000 | 8,000 | 10,000 | 1,000 | 0 | 0 |
Payments to Acquire Businesses, Net of Cash Acquired | ||||||
88,000 | 5,000 | 1,702,000 | 10,000 | 574,000 | 11,000 | 1,000 |
Purchase of investments | ||||||
- | - | - | - | 7,000 | 0 | 15,000 |
Change in restricted cash and cash equivalents, net | ||||||
- | - | - | - | - | - | 0 |
Other investing activities | ||||||
-3,000 | 0 | 1,000 | 0 | - | 1,000 | 0 |
Net cash used in investing activities | ||||||
-196,000 | -108,000 | -1,722,000 | -90,000 | -671,000 | -82,000 | -85,000 |
Cash flows from financing activities: | ||||||
Proceeds from issuance of common stock under employee stock plans | ||||||
67,000 | 64,000 | 51,000 | 43,000 | 26,000 | 0 | 0 |
Issuance of common stock under public offering | ||||||
0 | 0 | 444,000 | 0 | 0 | - | - |
Payment of taxes related to net share settlement of equity awards | ||||||
26,000 | 18,000 | 12,000 | 9,000 | - | - | - |
Proceeds from short-term borrowings | ||||||
0 | 40,000 | 212,000 | 0 | 0 | 2,000 | 0 |
Repayments of Debt | ||||||
500,000 | 300,000 | 323,000 | 1,000 | 0 | 37,000 | 0 |
Payment of acquisition-related contingent consideration | ||||||
0 | 6,000 | 0 | - | - | - | - |
Proceeds from issuance of long-term debt | ||||||
500,000 | 0 | 1,069,000 | 0 | 0 | 1,099,000 | 0 |
Debt issuance costs | ||||||
4,000 | 0 | 16,000 | 0 | 0 | 10,000 | 0 |
Excess tax benefit (deficiency) from share-based plans | ||||||
- | - | - | - | 4,000 | 4,000 | 0 |
Treasury stock repurchases | ||||||
159,000 | 120,000 | 0 | 62,000 | 0 | 0 | - |
Return of capital to Agilent | ||||||
- | - | - | - | 49,000 | 940,000 | 0 |
Net transfers from Agilent | ||||||
- | - | - | - | - | -217,000 | 481,000 |
Other financing activities | ||||||
0 | -1,000 | 0 | 0 | - | - | - |
Net Cash used in financing activities | ||||||
-122,000 | -341,000 | 1,425,000 | -29,000 | -19,000 | 335,000 | -481,000 |
Effect of exchange rate movements | ||||||
3,000 | -9,000 | 4,000 | -1,000 | -13,000 | -6,000 | 0 |
Net increase in cash, cash equivalents, and restricted cash | ||||||
683,000 | 97,000 | 35,000 | 300,000 | -327,000 | 810,000 | 0 |